Citations

Clear

5 citation(s) found for "McLean, Karen".

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Armstrong, Deborah K. , Barroilhet, Lisa , Chitiyo, Viola C., Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , McHale, Michael , Miller, David S. , Percac‐Lima, Sanja , Remmenga, Steven W., Schorge, John O., Vargas, Roberto , Hendrickson, Andrea Wahner, Werner, Theresa L. , Dwyer, Mary A., Hang, Lisa E., Miller, David S , Alvarez, Ronald D. , Backes, Floor , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Chitiyo, Viola, DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Leiserowitz, Gary S. , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen , Stewart, Daphne B. , Thaker, Premal H. , Zsíros, Emese

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 972-980

10.6004/jnccn.2022.0047 | PMID 36075393 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
Abstract 2248: Environmental factors associated with residual disease after ovarian cancer primary cytoreduction surgery
Phung, Minh Tung , Goode, Ellen L. , Goodman, Marc T. , Richardson, Jean , Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Gorp, Toon Van , Pike, Malcolm C. , Schildkraut, Joellen M. , Pearce, Celeste Leigh , Goodman, Marc T , Phung, Minh Tung , Berchuck, Andrew , Hanley, Gillian E. , Chase, Anne, Karlan, Beth Y. , Matsuo, Keitaro , McLean, Karen, Terry, Kathryn L. , DeFazio, Anna , Webb, Penelope M. , Pharoah, Paul D.P. , Ramus, Susan J.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 2248-2248

10.1158/1538-7445.am2022-2248 Get It

Abstract Background: Ovarian cancer is the deadliest gynecologic cancer. Standard treatments for advanced stage high-grade serous ovarian cancer, the most common type, include (1) primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy or (2) neoadjuvant chemotherapy (NACT) with interval debulking surgery. Patients in whom PCS is unlikely to yield optimal cytoreduction to no visible residual disease (R0) or who have medical contraindications to PCS are recommended to undergo NACT. Previous studies on associations between environmental factors and risk of any macroscopic residual disease have yielded inconsistent results. We aimed to (1) comprehensively examine the associations between demographic, lifestyle and reproductive factors and risk of residual disease after PCS; and (2) develop and internally validate a risk prediction model based on these factors. Methods: We used pooled data on 3,492 women who had PCS following a diagnosis with advanced stage high-grade serous ovarian, fallopian tube or primary peritoneal cancers from the Ovarian Cancer Association Consortium. Fifteen exposures of interest included age at diagnosis, menopausal status, race/ethnicity, education level, first-degree family history of ovarian cancer, endometriosis, smoking, body mass index, parity, incomplete pregnancy, tubal ligation, use of combined oral contraceptives, depot-medroxyprogesterone acetate, estrogen (ET), and combined estrogen-progestin therapy. We fit logistic regression models to examine each exposure-residual disease association in 80% of the data (n=2,794; random selection of participants). We developed a risk prediction model including the factors with p-values ≤0.2. Area under the receiver operating characteristic curve (AUC) was used to assess the model’s discrimination in the remaining 20% of the data (n=698). Results: Of the 3,492 participants, 2,003 (57%) had residual disease following PCS. Older age at diagnosis was associated with an increased risk of residual disease (OR=1.07 per five years, 95% CI 1.03-1.11). In contrast, a family history of ovarian cancer (OR=0.63, 95% CI 0.42-0.95) or ET use for 5+ years (OR=0.61, 95% CI 0.39-0.96) were associated with achieving R0. These above factors were included in the risk prediction model as were race/ethnicity, personal history of endometriosis, and smoking, whose p-values ≤0.2. The model showed modest performance in the validation set (AUC=0.64). Conclusions: Younger age at diagnosis, family history of ovarian cancer, and long-term ET use were associated with achieving R0 following PCS. Future studies incorporating genetic and clinical factors to improve the risk prediction for residual disease following PCS are warranted. Citation Format: Minh Tung Phung, Andrew Berchuck, Ellen L. Goode, Marc T. Goodman, Gillian E. Hanley, Jean Richardson, Bronwyn Grout, Anne Chase, Cindy McKinnon Deurloo, Beth Y. Karlan, Toon Van Gorp, Keitaro Matsuo, Karen McLean, Malcolm C. Pike, Joellen M. Schildkraut, Kathryn L. Terry, Anna DeFazio, Penelope M. Webb, Paul D. P. Pharoah, Susan J. Ramus, Celeste Leigh Pearce. Environmental factors associated with residual disease after ovarian cancer primary cytoreduction surgery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2248.
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival
Brieger, Katharine K. , Phung, Minh Tung , Mukherjee, Bhramar, Bakulski, Kelly M. , Anton-Culver, Hoda, Bandera, Elisa V. , Bowtell, David D.L., Cramer, Daniel W., DeFazio, Anna , Doherty, Jennifer A. , Fereday, Sian, Fortner, Renée T. , Goode, Ellen L., Goodman, Marc T., Menon, Usha , Moysich, Kirsten B., Qin, Bo , Ramus, Susan J. , Risch, Harvey A., Rossing, Mary Anne, Schildkraut, Joellen M., Trabert, Britton , Wentzensen, Nicolas, Wu, Anna H., Khoja, Lilah , Richardson, Jean , Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Odunsi, Kunle , Brenton, James D. , Terry, Kathryn L., Pharoah, Paul D.P., Berchuck, Andrew, Hanley, Gillian E., Pike, Malcolm C. , Pearce, Celeste Leigh, Goodman, Marc T. , Terry, Kathryn L. , Bowtell, David D.L. , Fereday, Sián , Hanley, Gillian E. , Fortner, Renée T , Gentry‐Maharaj, Aleksandra , Harris, Holly R , Matsuo, Keitaro , Menon, Usha , Modugno, Francesmary , Qin, Bo , Ramus, Susan J , Trabert, B , Vierkant, Robert A , Winham, Stacey J , Ziogas, Argyrios , Khoja, Lilah , Cho, Kathleen R , McLean, Karen , Richardson, Jean , Odunsi, Kunle , Nelson, Brad H , Brenton, James D , Webb, Penelope M , Pike, Malcolm C , Fazio, Anna de , Doherty, Jennifer A , Moysich, Kirsten , Bowtell, David D , Fereday, Sian , Goodman, Marc T , Brieger, Katharine K. , Phung, Minh Tung , Mukherjee, Bhramar, Bakulski, Kelly M. , Anton-Culver, Hoda, Bandera, Elisa V. , Cramer, Daniel W., Goode, Ellen L., Goodman, Marc T., Moysich, Kirsten B. , Risch, Harvey A., Rossing, Mary Anne, Schildkraut, Joellen M., Wentzensen, Nicolas, Wu, Anna H., Grout, Bronwyn, Chase, Anne, Deurloo, Cindy McKinnon, Pharoah, Paul D.P., Berchuck, Andrew, Pearce, Celeste Leigh

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 17, 2021 | Volume: 31 | Issue: 2 | Pages: 443-452

10.1158/1055-9965.epi-21-0977 | PMID 34789471 Get It

Abstract Background: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects. Methods: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data. Results: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11–1.54). Conclusions: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. Impact: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Chen, Lee-may, Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , Mahdi, Haider , McHale, Michael , Miller, David S. , O’Malley, David M. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Vargas, Roberto , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Miller, David S , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 8, 2021 | Volume: 19 | Issue: 2 | Pages: 191-226

10.6004/jnccn.2021.0007 | PMID 33545690 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Berek, Jonathan S. , Cristea, Mihaela , DeRosa, Marie, ElNaggar, Adam C. , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Liu, Joyce F. , Mahdi, Haider , Matei, Daniela , McHale, Michael , O’Malley, David M. , Penson, Richard T. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Sabbatini, Paul , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Matei, Daniela E , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Gershenson, David M. , Johnston, Carolyn , Leath, Charles A , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2019 | Volume: 17 | Issue: 8 | Pages: 896-909

10.6004/jnccn.2019.0039 | PMID 31390583 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.